In adjusted models, neither KIM-1 nor IL-18 improved discrimination for CI-AKI; the addition of OPN and CysC to the CI-AKI clinical model significantly increased statistical significance (from 0.69 to 0.73, p for change < 0.001) and would facilitate risk stratification for future cardiorenal outcomes or CKD progression. This evidence concerns the gene HAVCR1 and chronic kidney disease.